{"id":7163,"date":"2013-06-04T02:30:28","date_gmt":"2013-06-04T06:30:28","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=7163"},"modified":"2013-06-04T02:30:28","modified_gmt":"2013-06-04T06:30:28","slug":"tesaro-inc-nasdaqtsro-enters-into-partnership-for-clinical-trials","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/tesaro-inc-nasdaqtsro-enters-into-partnership-for-clinical-trials-7163","title":{"rendered":"TESARO Inc. (NASDAQ:TSRO) enters into Partnership for clinical trials"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 06\/04\/2013 (wallstreetpr) &#8211;\u00a0The share prices of TESARO Inc. (NASDAQ:TSRO) had surged by whopping 35.11 percent to close at $46.22 per share for the end of last trading session on Monday. The shares of the development stage, oncology focused pharmaceutical company had been trading in the range of $34.45 to $47.50 per share during the day. The recent surge in share prices had led TESARO Inc. (NASDAQ:TSRO) to hit new records of 52 week high price levels to $47.50 per share and the 52 week low price level of the company is at $11.05 per share.<\/p>\n<p style=\"text-align: justify;\"><b>Partnership for clinical trials of Niraparib<\/b><\/p>\n<p style=\"text-align: justify;\">TESARO Inc. (NASDAQ:TSRO) with main focus on development of therapeutic drugs for treatment of cancer had announced that it will be entering into partnership with Breast International Group and the European Organization for Research and Treatment of cancer for the clinical development of Phase III of its cancer drug niraparib. The present product candidates of TESARO Inc. (NASDAQ:TSRO) are aimed at treating cancer through non specific damage to cellular components or through the metabolism of alter cell or through the use of internal repair mechanisms to destroy the cancer cells.<\/p>\n<p style=\"text-align: justify;\">The recent news on partnership for the clinical trials of its drug had led TESARO Inc. (NASDAQ:TSRO) to surge in share prices and also witness heavy trading volumes. Nearly 1.58 million shares of the oncology drug company had been traded on Monday, while the average trading volume of the company is at 251,272 shares per day.<\/p>\n<p style=\"text-align: justify;\">TESARO Inc. (NASDAQ:TSRO) presently holds 32.58 million shares outstanding in the market with an institutional ownership of 89 percent.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 06\/04\/2013 (wallstreetpr) &#8211;\u00a0The share prices of TESARO Inc. (NASDAQ:TSRO) had surged by whopping 35.11 percent to close at $46.22 per share for the [&hellip;]<\/p>\n","protected":false},"author":15,"featured_media":7164,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[2236,264],"tags":[2132,2131],"stock_ticker":[],"class_list":["post-7163","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","category-health","tag-nasdaqtsro","tag-tesaro-inc-nasdaqtsro","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>TESARO Inc. (NASDAQ:TSRO) enters into Partnership for clinical trials - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/tesaro-inc-nasdaqtsro-enters-into-partnership-for-clinical-trials-7163\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TESARO Inc. (NASDAQ:TSRO) enters into Partnership for clinical trials - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 06\/04\/2013 (wallstreetpr) &#8211;\u00a0The share prices of TESARO Inc. (NASDAQ:TSRO) had surged by whopping 35.11 percent to close at $46.22 per share for the [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/tesaro-inc-nasdaqtsro-enters-into-partnership-for-clinical-trials-7163\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2013-06-04T06:30:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/Drug_AIDS02.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"768\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Benjamin Roussey\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Benjamin Roussey\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/tesaro-inc-nasdaqtsro-enters-into-partnership-for-clinical-trials-7163#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/tesaro-inc-nasdaqtsro-enters-into-partnership-for-clinical-trials-7163\"},\"author\":{\"name\":\"Benjamin Roussey\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d\"},\"headline\":\"TESARO Inc. (NASDAQ:TSRO) enters into Partnership for clinical trials\",\"datePublished\":\"2013-06-04T06:30:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/tesaro-inc-nasdaqtsro-enters-into-partnership-for-clinical-trials-7163\"},\"wordCount\":272,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/tesaro-inc-nasdaqtsro-enters-into-partnership-for-clinical-trials-7163#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/Drug_AIDS02.jpg\",\"keywords\":[\"NASDAQ:TSRO\",\"TESARO Inc. (NASDAQ:TSRO)\"],\"articleSection\":[\"Business\",\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/tesaro-inc-nasdaqtsro-enters-into-partnership-for-clinical-trials-7163#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/tesaro-inc-nasdaqtsro-enters-into-partnership-for-clinical-trials-7163\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/tesaro-inc-nasdaqtsro-enters-into-partnership-for-clinical-trials-7163\",\"name\":\"TESARO Inc. (NASDAQ:TSRO) enters into Partnership for clinical trials - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/tesaro-inc-nasdaqtsro-enters-into-partnership-for-clinical-trials-7163#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/tesaro-inc-nasdaqtsro-enters-into-partnership-for-clinical-trials-7163#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/Drug_AIDS02.jpg\",\"datePublished\":\"2013-06-04T06:30:28+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/tesaro-inc-nasdaqtsro-enters-into-partnership-for-clinical-trials-7163#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/tesaro-inc-nasdaqtsro-enters-into-partnership-for-clinical-trials-7163\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/tesaro-inc-nasdaqtsro-enters-into-partnership-for-clinical-trials-7163#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/Drug_AIDS02.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/Drug_AIDS02.jpg\",\"width\":1024,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/tesaro-inc-nasdaqtsro-enters-into-partnership-for-clinical-trials-7163#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TESARO Inc. (NASDAQ:TSRO) enters into Partnership for clinical trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d\",\"name\":\"Benjamin Roussey\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g\",\"caption\":\"Benjamin Roussey\"},\"description\":\"Benjamin Roussey is from Sacramento, California. He has two master\u2019s degrees and served four years in the U.S. Navy. His bachelor\u2019s degree is from CSUS (1999) where he was on a baseball pitching scholarship. His second master\u2019s degree is an MBA in Global Management from the University of Phoenix (2006). He has worked for small businesses, public agencies, and large corporations. He has lived in Korea and Saudi Arabia where he was an ESL instructor. Benjamin spends his time in between Northern California and Cabo San Lucas, Mexico, committing himself to his craft of freelance and website writing. http:\/\/www.facebook.com\/ben.rouss\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/benjamin-roussey\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"TESARO Inc. (NASDAQ:TSRO) enters into Partnership for clinical trials - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/tesaro-inc-nasdaqtsro-enters-into-partnership-for-clinical-trials-7163","og_locale":"en_US","og_type":"article","og_title":"TESARO Inc. (NASDAQ:TSRO) enters into Partnership for clinical trials - Wall Street PR","og_description":"Boston, MA 06\/04\/2013 (wallstreetpr) &#8211;\u00a0The share prices of TESARO Inc. (NASDAQ:TSRO) had surged by whopping 35.11 percent to close at $46.22 per share for the [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/tesaro-inc-nasdaqtsro-enters-into-partnership-for-clinical-trials-7163","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2013-06-04T06:30:28+00:00","og_image":[{"width":1024,"height":768,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/Drug_AIDS02.jpg","type":"image\/jpeg"}],"author":"Benjamin Roussey","twitter_misc":{"Written by":"Benjamin Roussey","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/tesaro-inc-nasdaqtsro-enters-into-partnership-for-clinical-trials-7163#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/tesaro-inc-nasdaqtsro-enters-into-partnership-for-clinical-trials-7163"},"author":{"name":"Benjamin Roussey","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d"},"headline":"TESARO Inc. (NASDAQ:TSRO) enters into Partnership for clinical trials","datePublished":"2013-06-04T06:30:28+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/tesaro-inc-nasdaqtsro-enters-into-partnership-for-clinical-trials-7163"},"wordCount":272,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/tesaro-inc-nasdaqtsro-enters-into-partnership-for-clinical-trials-7163#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/Drug_AIDS02.jpg","keywords":["NASDAQ:TSRO","TESARO Inc. (NASDAQ:TSRO)"],"articleSection":["Business","Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/tesaro-inc-nasdaqtsro-enters-into-partnership-for-clinical-trials-7163#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/tesaro-inc-nasdaqtsro-enters-into-partnership-for-clinical-trials-7163","url":"https:\/\/cablemanpro.com\/wallstreetpr\/tesaro-inc-nasdaqtsro-enters-into-partnership-for-clinical-trials-7163","name":"TESARO Inc. (NASDAQ:TSRO) enters into Partnership for clinical trials - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/tesaro-inc-nasdaqtsro-enters-into-partnership-for-clinical-trials-7163#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/tesaro-inc-nasdaqtsro-enters-into-partnership-for-clinical-trials-7163#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/Drug_AIDS02.jpg","datePublished":"2013-06-04T06:30:28+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/tesaro-inc-nasdaqtsro-enters-into-partnership-for-clinical-trials-7163#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/tesaro-inc-nasdaqtsro-enters-into-partnership-for-clinical-trials-7163"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/tesaro-inc-nasdaqtsro-enters-into-partnership-for-clinical-trials-7163#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/Drug_AIDS02.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/Drug_AIDS02.jpg","width":1024,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/tesaro-inc-nasdaqtsro-enters-into-partnership-for-clinical-trials-7163#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"TESARO Inc. (NASDAQ:TSRO) enters into Partnership for clinical trials"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d","name":"Benjamin Roussey","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g","caption":"Benjamin Roussey"},"description":"Benjamin Roussey is from Sacramento, California. He has two master\u2019s degrees and served four years in the U.S. Navy. His bachelor\u2019s degree is from CSUS (1999) where he was on a baseball pitching scholarship. His second master\u2019s degree is an MBA in Global Management from the University of Phoenix (2006). He has worked for small businesses, public agencies, and large corporations. He has lived in Korea and Saudi Arabia where he was an ESL instructor. Benjamin spends his time in between Northern California and Cabo San Lucas, Mexico, committing himself to his craft of freelance and website writing. http:\/\/www.facebook.com\/ben.rouss","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/benjamin-roussey"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/7163","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=7163"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/7163\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/7164"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=7163"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=7163"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=7163"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=7163"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}